Topic Menu
► Topic MenuTopic Editors


MRI and PET/MRI in Hematology and Oncology
Topic Information
Dear Colleagues,
Accurate staging and precise measurement of tumor burden are essential to plan effective therapy of cancer patients. Evaluation of therapeutic changes is equally essential to modify the therapeutic strategy. FDG-PET /CT has become a cornerstone in the staging and restaging of neoplasms, in the evaluation of therapeutic efficacy during or after treatment and in the planning of radiotherapy, proving to be more sensitive than contrast-enhanced CT in the staging of lymphoma and in the diagnosis of diffuse neoplasms.
To date, MRI has been considered only an alternative method for the diagnosis and staging of various hematologic and oncologic diseases especially in younger patients, due to the absence of ionizing radiation, high soft tissue contrast and good spatial resolution. The use of advanced sequences, such as DWI, however, has further improved the diagnostic accuracy of MRI in oncology. The recently developed whole body (WB) MRI technique has significantly increased the diagnostic accuracy of MRI in onco-hematological imaging, providing an excellent total body imaging.
In myeloma only WB-MRI is now recognized as a highly sensitive test for diagnosis and staging. Instead in lymphoma, WB-DWI-MRI merely serves as an alternative technique to FDG-PET/CT, especially in pediatric patients, although its use is increasingly important in adult patients as well. Despite the high sensitivity in the diagnosis and follow up of lymphomas and non-hematologic malignancies, WB DWI MRI is not recommended in current guidelines yet.
PET/MRI is a relatively new hybrid imaging technique, recently introduced into routine clinical practice. Several comparative studies between hybrid PET/CT and PET/MRI imaging techniques recently been performed in relatively small patient populations have provided preliminary satisfactory results in favour of MRI.
The aim of this issue is to discuss the current clinical applications of the up-to-date MRI techniques in oncology and hematology as well as to propose research topics in the field of hematology and oncology.
Prof. Dr. Francesca Maccioni
Prof. Dr. Leonardo Pace
Topic Editors
Keywords
• MRI
• Whole Body MRI
• Diffusion Weighted Imaging
• PET/MRI
• Haematology
• Oncology
• Lymphoma
• Myeloma
• Radiopharmaceuticals
• CNS tumor
• Head & neck tumor
• Liver cancer
• Gynecological cancer
• Musculoskeletal tumor
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC |
---|---|---|---|---|---|
![]()
Cancers
|
4.5 | 8.0 | 2009 | 17.4 Days | CHF 2900 |
![]()
Diagnostics
|
3.0 | 4.7 | 2011 | 20.3 Days | CHF 2600 |
![]()
Hemato
|
0.9 | 1.3 | 2020 | 30.6 Days | CHF 1000 |
![]()
Journal of Clinical Medicine
|
3.0 | 5.7 | 2012 | 16 Days | CHF 2600 |
![]()
Tomography
|
2.2 | 2.7 | 2015 | 23.8 Days | CHF 2400 |
Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.
MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:
- Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
- Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
- Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
- Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
- Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.